Works by Feng, Huaibao

Results: 13

Optimal Dosing Regimen for Epcoritamab, a Subcutaneous Bispecific Antibody, in Relapsed or Refractory Large B‐Cell Lymphoma.

Published in:

Clinical Pharmacology & Therapeutics, 2025, v. 117, n. 5, p. 1437, doi. 10.1002/cpt.3588

By:

Li, Tommy;
Gibiansky, Leonid;
Parikh, Apurvasena;
Putnins, Matthew;
Chiu, Christopher W.;
Sacchi, Mariana;
Feng, Huaibao;
Ahmadi, Tahamtan;
Gupta, Manish;
Xu, Steven

Publication type:

Article

The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit.

Published in:

American Journal of Hematology, 2015, v. 90, n. 5, p. E86, doi. 10.1002/ajh.23967

By:

Harrison, Simon J.;
Quach, Hang;
Link, Emma;
Feng, Huaibao;
Dean, Joanne;
Copeman, Michael;
Van De Velde, Helgi;
Schwarer, Anthony;
Baker, Bartrum;
Spencer, Andrew;
Catalano, John;
Campbell, Philip;
Augustson, Bradley;
Romeril, Ken;
Prince, Henry Miles

Publication type:

Article

Population Pharmacokinetics of Epcoritamab Following Subcutaneous Administration in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma: PPK of Epcoritamab SC in R/R B-NHL: T. Li et al.

Published in:

Clinical Pharmacokinetics, 2025, v. 64, n. 1, p. 127, doi. 10.1007/s40262-024-01464-2

By:

Li, Tommy;
Gibiansky, Leonid;
Parikh, Apurvasena;
van der Linden, Marcel;
Sanghavi, Kinjal;
Putnins, Matthew;
Sacchi, Mariana;
Feng, Huaibao;
Ahmadi, Tahamtan;
Gupta, Manish;
Xu, Steven

Publication type:

Article

Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma.

Published in:

Clinical Pharmacokinetics, 2012, v. 51, n. 12, p. 823, doi. 10.1007/s40262-012-0010-0

By:

Moreau, Philippe;
Karamanesht, Ievgenii I.;
Donmikova, Natalia;
Kyselyova, Maryna Y.;
Vilchevska, Kateryna V.;
Doronin, Vadim A.;
Schmidt, Alexander;
Hulin, Cyrille;
Leleu, Xavier;
Esseltine, Dixie-Lee;
Venkatakrishnan, Karthik;
Skee, Donna;
Huaibao Feng;
Girgis, Suzette;
Cakana, Andrew;
van de Velde, Helgi;
Deraedt, William;
Facon, Thierry

Publication type:

Article

Effect of Cytochrome P450 3A4 Inducers on the Pharmacokinetic, Pharmacodynamic and Safety Profiles of Bortezomib in Patients with Multiple Myeloma or Non-Hodgkin's Lymphoma.

Published in:

Clinical Pharmacokinetics, 2011, v. 50, n. 12, p. 781, doi. 10.2165/11594410-000000000-00000

By:

Hellmann, Andrzej;
Rule, Simon;
Walewski, Jan;
Shpilberg, Ofer;
Huaibao Feng;
de Velde, Helgi van;
Patel, Hamina;
Skee, Donna M.;
Girgis, Suzette;
Louw, Vernon J.

Publication type:

Article

A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.

Published in:

British Journal of Haematology, 2017, v. 178, n. 4, p. 547, doi. 10.1111/bjh.14708

By:

Laubach, Jacob P.;
Moslehi, Javid J.;
Francis, Sanjeev A.;
San Miguel, Jesús F.;
Sonneveld, Pieter;
Orlowski, Robert Z.;
Moreau, Philippe;
Rosiñol, Laura;
Faber, Edward A.;
Voorhees, Peter;
Mateos, Maria ‐ Victoria;
Marquez, Loreta;
Feng, Huaibao;
Desai, Avinash;
Velde, Helgi;
Elliott, Jennifer;
Shi, Hongliang;
Dow, Edward;
Jobanputra, Nishith;
Esseltine, Dixie ‐ Lee

Publication type:

Article

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up.

Published in:

British Journal of Haematology, 2015, v. 171, n. 3, p. 344, doi. 10.1111/bjh.13582

By:

Ludwig, Heinz;
Greil, Richard;
Masszi, Tamas;
Spicka, Ivan;
Shpilberg, Ofer;
Hajek, Roman;
Dmoszynska, Anna;
Paiva, Bruno;
Vidriales, María‐Belén;
Esteves, Graca;
Stoppa, Anne Marie;
Robinson, Don;
Chaturvedi, Shalini;
Ataman, Ozlem;
Enny, Christopher;
Feng, Huaibao;
Velde, Helgi;
Viterbo, Luisa

Publication type:

Article

Adaptive Group Sequential Test with Changing Patient Population.

Published in:

Journal of Biopharmaceutical Statistics, 2012, v. 22, n. 4, p. 662, doi. 10.1080/10543406.2012.678808

By:

Feng, Huaibao;
Liu, Qing

Publication type:

Article

Adaptive Group Sequential Test for Clinical Trials with Changing Patient Population.

Published in:

Journal of Biopharmaceutical Statistics, 2007, v. 17, n. 6, p. 1227, doi. 10.1080/10543400701645512

By:

Feng, Huaibao;
Shao, Jun;
Chow, Shein-Chung

Publication type:

Article

Daratumumab With Cetrelimab, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma.

Published in:

2021

By:

Cohen, Yael C.;
Oriol, Albert;
Wu, Ka Lung;
Lavi, Noa;
Vlummens, Philip;
Jackson, Carolyn;
Garvin, Wendy;
Carson, Robin;
Crist, Wendy;
Fu, Jiayu;
Feng, Huaibao;
Xie, Hong;
Schecter, Jordan;
San-Miguel, Jesús;
Lonial, Sagar

Publication type:

journal article

Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.

Published in:

2019

By:

Salles, Gilles;
Gopal, Ajay K.;
Minnema, Monique C.;
Wakamiya, Karen;
Feng, Huaibao;
Schecter, Jordan M.;
Wang, Michael

Publication type:

journal article

Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients With Relapsed or Refractory Multiple Myeloma.

Published in:

2018

By:

Chari, Ajai;
Arinsburg, Suzanne;
Jagannath, Sundar;
Satta, Toshihisa;
Treadwell, Ivey;
Catamero, Donna;
Morgan, Gillian;
Feng, Huaibao;
Uhlar, Clarissa;
Khan, Imran;
Doshi, Parul;
Usmani, Saad

Publication type:

journal article

Adaptive Choice of Group Sequential Boundary.

Published in:

Statistics in Biopharmaceutical Research, 2010, v. 2, n. 2, p. 199, doi. 10.1198/sbr.2009.0055

By:

Feng, Huaibao

Publication type:

Article